Protégé GPS Self-Expanding Peripheral Stent System; Protégé RX Self-Expanding Carotid Stent System
Medtronic Vascular, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
FDA database record P060001/S059, dated 2026-10-16, documents a 30-Day Notice for the Protégé GPS Self-Expanding Peripheral Stent System and Protégé RX Self-Expanding Carotid Stent System. The decision field states approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices. The supplement type is a 30-Day Notice and the supplement reason is listed as Process Change - Manufacturer/Sterilizer/Packager/Supplier.
This record does not represent a new approval of the stent systems themselves. It is a manufacturing process notice tied to the original PMA identifier P060001. The statement reports the purpose of the change but does not provide independent proof of safety or clinical effectiveness. Specific details about the previous incubation time, the new incubation time, or the biological indicator type are absent from the supplied fields.
FDA approval order statement
approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P060001/S059
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIM
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P060001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P060001 · Original PMA
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMS
P060001/S059 received
Application receipt date recorded by FDA.
P060001/S059 · FDA decision
30-Day Notice
P060001/S060 · Related supplement
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMS
Timeline entries are records held by MedtechLedger for P060001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA approval | Jan 24, 2007 | FDA | |
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Contego Medical, Inc. | PMA approval | Oct 11, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P060001/S059
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
